Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany

Zeitschrift fur Gastroenterologie

Volumn 50, Issue 5, 2012, Pages 441-444

  Mauss, S ^a   Berger, F ^a   Vogel, M ^b   Pfeiffer Vornkahl, H ^c   Alshuth, U ^d   Rockstroh, J K ^b   Niederau, C ^e   Huppe D ^f  

^a Center for HIV and Hepatogastroenterology   (Germany)

^b Department of Internal Medicine III ^*  (Germany)

^c Scientific Information and Communication MbH   (Germany)

^d ROCHE INNOVATION CENTER MUNICH   (Germany)

^e Katholische Kliniken Oberhausen   (Germany)

^f Practice for Gastroenterology   (Germany)

Author keywords

HCV genotype 5; HCV genotype 6; HCV therapy; hepatitis C; viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIA; BLOOD TRANSFUSION; CHRONIC HEPATITIS; COHORT ANALYSIS; DATA BASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; GERMANY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIGRATION; NONHUMAN; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS GENOME; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREVALENCE; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861109701     PISSN: 00442771     EISSN: 14397803     Source Type: Journal    
DOI: 10.1055/s-0031-1282072     Document Type: Article

References (11)

1. Antaki N, Craxi A, Kamal S et al. The neglected hepatitis C virus genotypes 5 and 6: an international consensus report. Liver Int: 2010; 30 342 355
2. Legrand-Abravanel F, Sandres-Saune K, Barange K et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis: 2004; 189 1397 1400 (Pubitemid 38543588)
3. D'Heygere F, George C, Van Vlieberghe H et al. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective trials. J Med Virol: 2011; 83 815 819
4. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N et al. Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand. J Med Virol: 2010; 82 257 262
5. Pham DA, Leuangwutiwong P, Jittmittraphap A et al. High prevalence of hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol: 2009; 27 153 160
6. Lam KD, Trinh HN, Do ST et al. Randomized controlled trial of pegylated interferon alfa-2a and ribavirin in treatment-nave chronic hepatitis C genotype 6. Hepatology: 2010; 52 1573 1580
7. Fung J, Ching-Lung L, Hung I et al. Chronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin. J Infect Dis: 2008; 198 808 812
8. Antaki N, Hermes A, Hadad M et al. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat: 2008; 15 383 386 (Pubitemid 351473624)
9. Sarrazin C, Berg T, Ross RS et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol: 2010; 48 289 351
10. Hüppe D, Zehnter E, Mauss S et al. Epidemiology of chronic hepatitis C in Germany an analysis of 10,326 patients in hepatitis centres and outpatient units. Z Gastroenterol: 2008; 46 34 44 (Pubitemid 351261948)
11. Tsang OT, Zee JS, Chan JM et al. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. J Gastroenterol Hepatol: 2010; 25 766 771